AUTHOR=Gomez-Lumbreras Ainhoa , Vilaplana-Carnerero Carles , Lestón Vázquez Marta , Vedia Cristina , Morros Rosa , Giner-Soriano Maria 

TITLE=Treatment of hypertension during pregnancy: a cohort of pregnancy episodes from the SIDIAP database, Catalonia, Spain

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 15 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1346357

DOI=10.3389/fphar.2024.1346357

ISSN=1663-9812

ABSTRACT=Background: Hypertension during pregnancy is one of the most frequent causes of maternal and fetal morbimortality. Perinatal and maternal death and disability rates have decreased a 30%, but hypertension during pregnancy has increased around 10% in the last 30 years. This research aimed to describe the pharmacological treatment and pregnancy outcomes of pregnancies with hypertension.Methods: observational cohort study from the Information System for the Development of Research in Primary Care (SIDIAP) database. Pregnancy episodes with hypertension (ICD-10 codes for hypertension, I10-I15 and O10-O16) were identified. Antihypertensives were classified according to the ATC WHO classification: β-blocking agents (BB), calcium-channel blockers (CCB), agents acting on the reninangiotensin system (RAS agents), diuretics and, antiadrenergic agents. Exposure was defined for hypertension pregnancies with ≥2 prescriptions during the pregnancy episode. Descriptive statistics for diagnoses and treatments were calculated.Results: 4,839 pregnancies with hypertension diagnosis formed the study cohort. There were 1,944 (40.2%) pregnancies exposed to an antihypertensive medication. There were differences in mother's age, BMI, and alcohol intake between pregnancies exposed to antihypertensive medications and not exposed.BB were the most used (n=1,160 pregnancy episodes; 59.7%) followed by RAS agents (n=825, 42.4%), and CCB were the less used (n=347, 17.8%).Pregnancies with hypertension were exposed to antihypertensive medications, mostly BB. We plan to conduct a study focus on the RAS agents use during pregnancy and its outcomes in the offspring.